Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type II Diabetes Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes

NCT02762708
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass (RYGB), Caloric Restriction, Exendin-9,39, Normal Saline
Procedure · Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

NCT00957268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Miami, Florida • Pineallas Park, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Not applicable Interventional Results available

Technology-assisted Case Management in Adults With Type 2 Diabetes

NCT01373489
View directory record Official record
Conditions
Diabetes
Interventions
Technology-Assisted Case Management
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 120 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 26, 2026, 11:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study

NCT06730113
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 25 Years
Enrollment
930 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2033
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Sep 26, 2026, 11:59 AM EDT
Completed No phase listed Observational

TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study

NCT01364350
View directory record Official record
Conditions
Diabetes Mellitus Type 2 in Obese
Interventions
standard of care in general clinical practice
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 24 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Potatoes on Markers of Cardiometabolic Health

NCT03495284
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
Potato-based side dish, Refined grain-based
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
25 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus

NCT00495885
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
volinanserin (M100907), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 26, 2026, 11:59 AM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 26, 2026, 11:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Noninvasive Transcutaneous Glucometer Development

NCT01168076
View directory record Official record
Conditions
Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
InLight Solutions
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise and Activity Guidance in Older Adults With Diabetes

NCT00344240
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Functional circuit training with lifestyle behavior
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

NCT06542874
View directory record Official record
Conditions
Type 2 Diabetes (T2D)
Interventions
NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 11:59 AM EDT
Not listed Not applicable Interventional

The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study

NCT01323114
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Laparoscopic duodenal exclusion, Conventional Medical Treatment
Procedure · Other
Lead sponsor
McKenzie Health System
Other
Eligibility
20 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Sandusky, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GZR-18, Placebo
Drug · Other
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 26, 2026, 11:59 AM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Not applicable Interventional Results available

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 26, 2026, 11:59 AM EDT
Active, not recruiting No phase listed Observational

Biological Sample Repository for Gastrointestinal Disorders

NCT05874726
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions
Blood Collection, Urine Collection, Tissue Sample Collection
Diagnostic Test
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

NCT05352815
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
110
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 26, 2026, 11:59 AM EDT
Withdrawn Not applicable Interventional

Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study

NCT04283617
View directory record Official record
Conditions
Diabete Type 2
Interventions
Intensification of insulin regimen/Nutrition
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 26, 2026, 11:59 AM EDT
Recruiting Phase 2 Interventional

NAD Augmentation in Diabetes Kidney Disease

NCT05759468
View directory record Official record
Conditions
Type2diabetes, Diabetic Kidney Disease
Interventions
Investigational Product - MIB 626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 26, 2026, 11:59 AM EDT
Not listed No phase listed Observational

Sleep Apnea in Look AHEAD (Action for Health in Diabetes)

NCT00194259
View directory record Official record
Conditions
Obstructive Sleep Apnea, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
45 Years to 75 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 26, 2026, 11:59 AM EDT
Completed No phase listed Observational Results available

Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

NCT05734989
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
BP, HbA1c, PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD
Diagnostic Test · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians

NCT02266576
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Metabolic Syndrome, Insulin Resistance
Interventions
Standard DPP, Enhanced DPP
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 26, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients

NCT02551640
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Prediabetic State, Hypertension, Prehypertension, Obesity
Interventions
FeatForward App (on study smartphone)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Charlestown, Massachusetts • Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 26, 2026, 11:59 AM EDT